 AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients Los Gatos, Calif., Jan. 17, 2023 GLOBE NEWSWIRE Aridis Pharmaceuticals, Inc. NASDAQ: ARDS, a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced... The post New Approaches to Treating Infections in Cystic Fibrosis Patients AR 5... 